[
  {
    "ts": null,
    "headline": "RFK Jr. Makes Good On Promise To End Covid Vaccine Mandate. BioNTech Tumbles.",
    "summary": "BioNTech stock skidded Wednesday after the Food and Drug Administration ended its broad authorization of Covid vaccines in the U.S.",
    "url": "https://finnhub.io/api/news?id=1a299388f40e08b9bb9af5c91fbd4c1d220613b271a8129aa57f00d003fff393",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756319149,
      "headline": "RFK Jr. Makes Good On Promise To End Covid Vaccine Mandate. BioNTech Tumbles.",
      "id": 136540038,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "BioNTech stock skidded Wednesday after the Food and Drug Administration ended its broad authorization of Covid vaccines in the U.S.",
      "url": "https://finnhub.io/api/news?id=1a299388f40e08b9bb9af5c91fbd4c1d220613b271a8129aa57f00d003fff393"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Mixed Late Afternoon",
    "summary": "Health care stocks were mixed late Wednesday afternoon, with the NYSE Health Care Index adding 0.1%",
    "url": "https://finnhub.io/api/news?id=23c19e1db3fa6aa7aa1650e2689e1f433be52d73522c2ed31b8d5231b86c4102",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756323715,
      "headline": "Sector Update: Health Care Stocks Mixed Late Afternoon",
      "id": 136541216,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Health care stocks were mixed late Wednesday afternoon, with the NYSE Health Care Index adding 0.1%",
      "url": "https://finnhub.io/api/news?id=23c19e1db3fa6aa7aa1650e2689e1f433be52d73522c2ed31b8d5231b86c4102"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Advance Wednesday Afternoon",
    "summary": "Health care stocks rose Wednesday afternoon with the NYSE Health Care Index adding 0.2% and the Heal",
    "url": "https://finnhub.io/api/news?id=5cd95580d17289856d993b9c007e4d390a9e1b2274662960bb75090d5b9887fe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756317546,
      "headline": "Sector Update: Health Care Stocks Advance Wednesday Afternoon",
      "id": 136541206,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Health care stocks rose Wednesday afternoon with the NYSE Health Care Index adding 0.2% and the Heal",
      "url": "https://finnhub.io/api/news?id=5cd95580d17289856d993b9c007e4d390a9e1b2274662960bb75090d5b9887fe"
    }
  },
  {
    "ts": null,
    "headline": "Unusual Put Option Activity in Pfizer Stock - Have Investors Turned Bearish?",
    "summary": "Barchart reports that Pfizer stock is showing unusual put option activity in yesterday's trading. Does that mean investors have turned bearish? Not necessarily, especially given the company's upgraded guidance.",
    "url": "https://finnhub.io/api/news?id=8f7ba892d8bece0a058c5188b3b0edb27df0bd0973d1e91199ed6ff32bd2d027",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756315802,
      "headline": "Unusual Put Option Activity in Pfizer Stock - Have Investors Turned Bearish?",
      "id": 136557971,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Barchart reports that Pfizer stock is showing unusual put option activity in yesterday's trading. Does that mean investors have turned bearish? Not necessarily, especially given the company's upgraded guidance.",
      "url": "https://finnhub.io/api/news?id=8f7ba892d8bece0a058c5188b3b0edb27df0bd0973d1e91199ed6ff32bd2d027"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Finally Some Fortune, Plus Twenty High-Quality Dividend Growth Valuations",
    "summary": "Discover high-quality dividend-growth stocks near 52-week lows. Explore Pfizer's strong dividend and valuations, plus other top picks like Merck and Qualcomm.",
    "url": "https://finnhub.io/api/news?id=ec425284e980cf083d7d06feec4294590bc48a5d33b2fdd798c828b58de26570",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756315645,
      "headline": "Pfizer: Finally Some Fortune, Plus Twenty High-Quality Dividend Growth Valuations",
      "id": 136542130,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2203006359/image_2203006359.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover high-quality dividend-growth stocks near 52-week lows. Explore Pfizer's strong dividend and valuations, plus other top picks like Merck and Qualcomm.",
      "url": "https://finnhub.io/api/news?id=ec425284e980cf083d7d06feec4294590bc48a5d33b2fdd798c828b58de26570"
    }
  },
  {
    "ts": null,
    "headline": "New Covid-19 Boosters Are Coming Soon. Not Everyone Will Be Eligible to Get One.",
    "summary": "The Food and Drug Administration approved shots from Pfizer, Moderna and Novavax, but for a narrower population.",
    "url": "https://finnhub.io/api/news?id=ea4e3f36b47db4a3426c20b44d91dbd2e7c27f056f00c0af8318cb2929301611",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756314720,
      "headline": "New Covid-19 Boosters Are Coming Soon. Not Everyone Will Be Eligible to Get One.",
      "id": 136539697,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Food and Drug Administration approved shots from Pfizer, Moderna and Novavax, but for a narrower population.",
      "url": "https://finnhub.io/api/news?id=ea4e3f36b47db4a3426c20b44d91dbd2e7c27f056f00c0af8318cb2929301611"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19",
    "summary": "The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1Shipping of the LP.8.1-adapted vaccine will begin immediately to ensure robust supply and rapid access of this season’s vaccine in pharmacies, hospitals, and clinics across the country NEW YORK and MAINZ, GERMANY, AUGUST 27, 2025 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced the U.S. Food and Drug",
    "url": "https://finnhub.io/api/news?id=aaa36e3a50d3bc27c0ad09c9ef610686abf9f9f53b26fbe91fd0a4bd62392eac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756313400,
      "headline": "Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19",
      "id": 136539698,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1Shipping of the LP.8.1-adapted vaccine will begin immediately to ensure robust supply and rapid access of this season’s vaccine in pharmacies, hospitals, and clinics across the country NEW YORK and MAINZ, GERMANY, AUGUST 27, 2025 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced the U.S. Food and Drug",
      "url": "https://finnhub.io/api/news?id=aaa36e3a50d3bc27c0ad09c9ef610686abf9f9f53b26fbe91fd0a4bd62392eac"
    }
  },
  {
    "ts": null,
    "headline": "Will Camzyos Strengthen BMY's Cardiovascular Portfolio?",
    "summary": "Bristol Myers leans on Eliquis and surging Camzyos sales to offset looming generics, while its pipeline candidate milvexian readouts are near.",
    "url": "https://finnhub.io/api/news?id=6dd2c50f4ff131f4e4e9576cb60563591f4426ac4f6caf4c37bf354484d278e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756303500,
      "headline": "Will Camzyos Strengthen BMY's Cardiovascular Portfolio?",
      "id": 136539572,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Bristol Myers leans on Eliquis and surging Camzyos sales to offset looming generics, while its pipeline candidate milvexian readouts are near.",
      "url": "https://finnhub.io/api/news?id=6dd2c50f4ff131f4e4e9576cb60563591f4426ac4f6caf4c37bf354484d278e3"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves Pfizer Covid Vaccine but Adds Restrictions on Its Use",
    "summary": "FDA Approves Pfizer Covid Vaccine but Adds Restrictions on Its Use",
    "url": "https://finnhub.io/api/news?id=477aa9d681e268075417c12404e833b0beca58a7a7d3c5ba49504e827c7382f1",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756302960,
      "headline": "FDA Approves Pfizer Covid Vaccine but Adds Restrictions on Its Use",
      "id": 136572637,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "FDA Approves Pfizer Covid Vaccine but Adds Restrictions on Its Use",
      "url": "https://finnhub.io/api/news?id=477aa9d681e268075417c12404e833b0beca58a7a7d3c5ba49504e827c7382f1"
    }
  },
  {
    "ts": null,
    "headline": "My 3 Favorite Stocks to Buy Right Now",
    "summary": "Contrary to a common assumption at this time, not every stock is priced too richly or poses too much risk. Several underappreciated and undervalued names are just waiting to be found.",
    "url": "https://finnhub.io/api/news?id=5c9c5ad47420d627cfdffdc181bb0a20b74931b5b9a4ee6e4b598a7fe15ffe94",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756302300,
      "headline": "My 3 Favorite Stocks to Buy Right Now",
      "id": 136536616,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Contrary to a common assumption at this time, not every stock is priced too richly or poses too much risk. Several underappreciated and undervalued names are just waiting to be found.",
      "url": "https://finnhub.io/api/news?id=5c9c5ad47420d627cfdffdc181bb0a20b74931b5b9a4ee6e4b598a7fe15ffe94"
    }
  },
  {
    "ts": null,
    "headline": "Renovaro Inc. Announces Corporate Name Change to Lunai Bioworks, Inc., Reflecting Strategic Focus on AI-Driven Biodefense, Drug Discovery and Advanced Diagnostics",
    "summary": "LOS ANGELES, CALIFORNIA / ACCESS Newswire / August 27, 2025 / Renovaro Inc. (NASDAQ:RENB) today announced that it will change its corporate name to Lunai Bioworks, Inc. to better reflect its strategic direction and growing expertise in AI-powered ...",
    "url": "https://finnhub.io/api/news?id=277eef0b1271221f01143c765ef5e97db3e87248c0485139023b0f0823dff71d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756302300,
      "headline": "Renovaro Inc. Announces Corporate Name Change to Lunai Bioworks, Inc., Reflecting Strategic Focus on AI-Driven Biodefense, Drug Discovery and Advanced Diagnostics",
      "id": 136536615,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "LOS ANGELES, CALIFORNIA / ACCESS Newswire / August 27, 2025 / Renovaro Inc. (NASDAQ:RENB) today announced that it will change its corporate name to Lunai Bioworks, Inc. to better reflect its strategic direction and growing expertise in AI-powered ...",
      "url": "https://finnhub.io/api/news?id=277eef0b1271221f01143c765ef5e97db3e87248c0485139023b0f0823dff71d"
    }
  },
  {
    "ts": null,
    "headline": "ADVANCE 2025 Returns September 17 in New York City Featuring Global CMOs, Big Tech Leaders, and Wyclef Jean",
    "summary": "NEW YORK, August 27, 2025--Smartly, the AI-powered advertising technology platform, today announced the lineup for its flagship event, ADVANCE, on September 17 at Skylight at The Refinery in New York City. Now in its second year, ADVANCE is where global brands, agencies, and platforms set the agenda for the future of advertising.",
    "url": "https://finnhub.io/api/news?id=2c796354618d49eccc81ddcc0a954695733618eabbafacaba09e3b5a9cf43c4a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756299540,
      "headline": "ADVANCE 2025 Returns September 17 in New York City Featuring Global CMOs, Big Tech Leaders, and Wyclef Jean",
      "id": 136536215,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, August 27, 2025--Smartly, the AI-powered advertising technology platform, today announced the lineup for its flagship event, ADVANCE, on September 17 at Skylight at The Refinery in New York City. Now in its second year, ADVANCE is where global brands, agencies, and platforms set the agenda for the future of advertising.",
      "url": "https://finnhub.io/api/news?id=2c796354618d49eccc81ddcc0a954695733618eabbafacaba09e3b5a9cf43c4a"
    }
  },
  {
    "ts": null,
    "headline": "LLY vs. PFE: Which Pharma Giant Is the Better Pick for Investors?",
    "summary": "Pfizer's cost cuts, new products and cheaper valuation give it an edge over Eli Lilly despite LLY's strong GLP-1 momentum.",
    "url": "https://finnhub.io/api/news?id=0d7fb7dee8f54f0b6063611503ff4a77f6f85988f104bf3aa171a69729c5e295",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756296480,
      "headline": "LLY vs. PFE: Which Pharma Giant Is the Better Pick for Investors?",
      "id": 136536299,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer's cost cuts, new products and cheaper valuation give it an edge over Eli Lilly despite LLY's strong GLP-1 momentum.",
      "url": "https://finnhub.io/api/news?id=0d7fb7dee8f54f0b6063611503ff4a77f6f85988f104bf3aa171a69729c5e295"
    }
  },
  {
    "ts": null,
    "headline": "HER2+ Breast Cancer Clinical Trials Analysis Report 2025 - Enhance Your Understanding of Trial Counts and Enrollment Trends Across G7 & E7 Countries",
    "summary": "Featuring Roche, Pfizer, GSK, Novartis, and AstraZeneca Among Other Industry PlayersDublin, Aug. 27, 2025 (GLOBE NEWSWIRE) -- The \"Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) - Global Clinical Trials Review, 2025\" has been added to ResearchAndMarkets.com's offering. The report provides an in-depth analysis of the clinical trial landscape for HER2+ Breast Cancer. It offers crucial data on trial numbers, enrollment, and regional distribution, allowing stak",
    "url": "https://finnhub.io/api/news?id=a8346d3c26cee54d1fd947600a13011c313b4937895ae28f0caaab767135e4af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756289160,
      "headline": "HER2+ Breast Cancer Clinical Trials Analysis Report 2025 - Enhance Your Understanding of Trial Counts and Enrollment Trends Across G7 & E7 Countries",
      "id": 136536619,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Featuring Roche, Pfizer, GSK, Novartis, and AstraZeneca Among Other Industry PlayersDublin, Aug. 27, 2025 (GLOBE NEWSWIRE) -- The \"Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) - Global Clinical Trials Review, 2025\" has been added to ResearchAndMarkets.com's offering. The report provides an in-depth analysis of the clinical trial landscape for HER2+ Breast Cancer. It offers crucial data on trial numbers, enrollment, and regional distribution, allowing stak",
      "url": "https://finnhub.io/api/news?id=a8346d3c26cee54d1fd947600a13011c313b4937895ae28f0caaab767135e4af"
    }
  },
  {
    "ts": null,
    "headline": "Dyslipidemia Market Research Report 2025-2035 | Competitive Analysis of Amgen, Sanofi, Regeneron, Pfizer, Novartis, Viatris, AbbVie, AstraZeneca, Horizon Therapeutics, Esperion Therapeutic",
    "summary": "Dyslipidemia, linked to elevated cardiovascular disease risk, is benefiting from advancements in lipid profiling and genetic testing, catalyzing demand for personalized treatments. Statins dominate therapy, supported by PCSK9 inhibitors and RNA-based medicines. However, challenges like medication non-compliance, side effects, and high drug costs, especially in lower-income regions, impede market expansion. Yet, proactive government initiatives and heightened research funding are improving treatm",
    "url": "https://finnhub.io/api/news?id=459030ebf78534849e2c06f68d0a59a57cd09453cecbb0b13f1d5e1fe019216b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756285140,
      "headline": "Dyslipidemia Market Research Report 2025-2035 | Competitive Analysis of Amgen, Sanofi, Regeneron, Pfizer, Novartis, Viatris, AbbVie, AstraZeneca, Horizon Therapeutics, Esperion Therapeutic",
      "id": 136536358,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Dyslipidemia, linked to elevated cardiovascular disease risk, is benefiting from advancements in lipid profiling and genetic testing, catalyzing demand for personalized treatments. Statins dominate therapy, supported by PCSK9 inhibitors and RNA-based medicines. However, challenges like medication non-compliance, side effects, and high drug costs, especially in lower-income regions, impede market expansion. Yet, proactive government initiatives and heightened research funding are improving treatm",
      "url": "https://finnhub.io/api/news?id=459030ebf78534849e2c06f68d0a59a57cd09453cecbb0b13f1d5e1fe019216b"
    }
  },
  {
    "ts": null,
    "headline": "Chronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun Pharma",
    "summary": "The global chronic inducible urticaria (CIndU) market is experiencing significant transformation due to rising prevalence, advancements in diagnostics, and targeted immunotherapies. Affecting 0.1% to 3% of the population, CIndU is linked to conditions like allergies and autoimmune diseases. Market growth is propelled by insights into immune mechanisms and increasing awareness among healthcare providers. Emerging diagnostic tools and biologic therapies, such as monoclonal antibodies, enhance trea",
    "url": "https://finnhub.io/api/news?id=9d461e0b4d97e55d511f3c6e3d7bd785423f7c2d101af7c9409b9c8f2264c2be",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756284600,
      "headline": "Chronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun Pharma",
      "id": 136536324,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The global chronic inducible urticaria (CIndU) market is experiencing significant transformation due to rising prevalence, advancements in diagnostics, and targeted immunotherapies. Affecting 0.1% to 3% of the population, CIndU is linked to conditions like allergies and autoimmune diseases. Market growth is propelled by insights into immune mechanisms and increasing awareness among healthcare providers. Emerging diagnostic tools and biologic therapies, such as monoclonal antibodies, enhance trea",
      "url": "https://finnhub.io/api/news?id=9d461e0b4d97e55d511f3c6e3d7bd785423f7c2d101af7c9409b9c8f2264c2be"
    }
  },
  {
    "ts": null,
    "headline": "Trump Administration Plans To Pull COVID-19 Vaccines Off Market 'Within Months'",
    "summary": "The Trump administration is preparing to remove COVID-19 vaccines from the U.S. market \"within months,\" according to a close associate of Health and Human Services Secretary Robert F. Kennedy Jr. Shortly after the update, COVID-19 vaccine stocks, ...",
    "url": "https://finnhub.io/api/news?id=77dc9df5cd4ac485649fa3adce84d493276ea01777881d874b79d7f737013cad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756254667,
      "headline": "Trump Administration Plans To Pull COVID-19 Vaccines Off Market 'Within Months'",
      "id": 136536543,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Trump administration is preparing to remove COVID-19 vaccines from the U.S. market \"within months,\" according to a close associate of Health and Human Services Secretary Robert F. Kennedy Jr. Shortly after the update, COVID-19 vaccine stocks, ...",
      "url": "https://finnhub.io/api/news?id=77dc9df5cd4ac485649fa3adce84d493276ea01777881d874b79d7f737013cad"
    }
  }
]